Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
VelosBio
AddedFeb 13, 2024
UpdatedJun 18, 2026
VelosBio

VelosBio

Acquired

VelosBio Inc.: A biopharmaceutical company specializing in novel cancer therapeutics.

HQ
San Diego, CA, US
Founded
2017
Overview
Compare
Fundraising
Employees

VelosBio Inc. is a biopharmaceutical company dedicated to developing novel cancer therapeutics. The company focuses on targeting cell-surface proteins to create innovative treatments for cancer patients. VelosBio's mission is to improve the lives of those affected by cancer through cutting-edge science and targeted therapies.

VelosBio has made significant strides in the field of oncology, contributing to advancements in cancer treatment. The company's impactful research and development efforts have positioned it as a leader in the biopharmaceutical industry, driving progress in cancer therapeutics.

VelosBio - Similar Companies

Veloce BioPharma logo

Veloce BioPharma

Kronos Bio logo

Kronos Bio

Oncolix logo

Oncolix

Palm Therapeutics logo

Palm Therapeutics

Exovita Biosciences logo

Exovita Biosciences

Sporos Bioventures logo

Sporos Bioventures

Velorum Therapeutics logo

Velorum Therapeutics

velorumtx.com

Telo Therapeutics logo

Telo Therapeutics

A2 Biotherapeutics logo

A2 Biotherapeutics

a2bio.com

Vanquish Oncology logo

Vanquish Oncology

Kestrel Therapeutics logo

Kestrel Therapeutics

Vita Therapeutics logo

Vita Therapeutics

Fuse Biotherapeutics logo

Fuse Biotherapeutics

fusebiotx.com

Cello Therapeutics logo

Cello Therapeutics

cellothera.com

Outpace Bio logo

Outpace Bio

outpacebio.com

VelosBio - Quick Facts

Who are VelosBio's competitors?

Companies similar to VelosBio include Veloce BioPharma, Kronos Bio, Oncolix and Palm Therapeutics.

When was VelosBio founded?

VelosBio was founded in 2017.

Where is VelosBio's headquarters located?

VelosBio's headquarters is located in San Diego, CA, US.

When was VelosBio's last funding round?

VelosBio's most recent funding round was for $137M (USD) in July 2020.

How much has VelosBio raised to-date?

As of Jul 8, 2020, VelosBio has raised a total of $202.7M (USD).

VelosBio - Classification

Ownership
  • Equity
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Therapeutics
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified